Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation

Intracerebral Hemorrhage Clinical Trial

— MISTIE  

Official title:

Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00224770
• Other study ID #: ICH01
• Secondary ID: R01NS046309
• Status: Completed
• Phase: Phase 2
• First received: September 21, 2005
• Last updated: June 17, 2015
• Start date: August 2005
• Est. completion date: April 2013

Study information

• Verified date: June 2015
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to determine the safety of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove intracerebral hemorrhage (ICH). The ICES arm of the trial will determine the safety of endoscopic surgery to remove ICH. All MISTIE intention to treat subjects represent the hypothesized test group. The ICES cohort is to be analyzed separately.

Description:

The purpose of this trial is to determine the safety of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove intracerebral hemorrhage (ICH). The procedure is to use image-based surgery (MRI or CT) to provide catheter access to ICH for the intervention, which is a one-time clot aspiration followed by instillation of rt-PA over 72 hours.

The Intraoperative stereotactic CT-guided Endoscopic Surgery (ICES) arm of the trial will determine the safety, feasibility and effectiveness of endoscopic surgery to remove ICH. This tests the first step of the MISTIE surgical procedure with an endoscope, not a rigid cannula.

We propose to test if these interventions facilitate more rapid and complete recovery of function and decreased mortality from this condition compared to conventional medical management without subjecting the patient to craniotomy. The specific objective of this trial is to test the safety of these interventions and assess their ability to remove blood clot from brain tissue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 141
• Est. completion date: April 2013
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age 18-80

• GCS < 14 or a NIHSS > or equal to 6

• Spontaneous supratentorial ICH > or equal to 20cc

• Symptoms less than 12 hours prior to diagnostic CT scan (an unknown time of symptom onset is exclusionary)

• Intention to initiate surgery within 48 hours after diagnostic CT

• First dose can be given within 54 hours after diagnostic CT (delays for post surgical stabilization of catheter bleeding or because of unanticipated surgical delay are acceptable with approved waiver from the coordinating center) (Does not apply to ICES Tier)

• Six-hour clot size equal to the most previous clot size + 5 cc (as determined by an additional CT scan at least 6 hours after the initial stability scan (A*B*C)/2 method)

• SBP < 200 mmHg sustained for 6 hours recorded closest to time of randomization

• Historical Rankin score of 0 or 1

• Negative pregnancy test

Exclusion Criteria:

• Infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as demonstrated by radiograph or complete third nerve palsy)

• Patients with platelet count < 100,000, INR > 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization

• Clotting disorders

• Any concurrent serious illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease

• Patients with a mechanical valve

• Patients with unstable mass or evolving intracranial compartment syndrome

• Ruptured aneurysm, AVM, vascular anomaly

• Greater than 80 years (higher incidence of amyloid)

• Under 18 years of ag e (high incidence of occult vascular malformation)

• Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state)

• Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4

• Historical Rankin score greater than or equal to 2

• Intraventricular hemorrhage requiring external ventricular drainage

• Internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts (Does not apply to ICES Tier)

• Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or site of recent surgical intervention (Does not apply to ICES Tier)

• Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, and subacute bacterial endocarditis (Does not apply to ICES Tier)

• In the investigator's opinion, the patient is unstable and would benefit from a specific intervention rather than supportive care plus or minus MIS+rtPA

• Prior enrollment in the study

• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

• Participation in another simultaneous trial of ICH treatment.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cerebral Hemorrhage
• Hemorrhage
• Intracerebral Hemorrhage

Intervention

Drug:
• MIS+Cathflo Activase (drug)
MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.

Procedure:
• Intraoperative stereotactic CT-Guided Endoscopic Surgery
Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.

Locations

Country	Name	City	State
Canada	Montreal Neurological Institute at McGill University	Montreal	Quebec
Germany	University of Heidelberg	Heidelberg
United Kingdom	Newcastle General Hospital	Newcastle
United States	Johns Hopkins University/Bayview Medical Center	Baltimore	Maryland
United States	University of Maryland Medical Systems	Baltimore	Maryland
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Rush University	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	University of Cincinnati	Cincinnati	Ohio
United States	Case Western University	Cleveland	Ohio
United States	Henry Ford Health System	Detroit	Michigan
United States	JFK Medical Center New Jersey	Edison	New Jersey
United States	NorthShore University Health System	Evanston	Illinois
United States	Hartford Hospital	Hartford	Connecticut
United States	University of Texas, Houston	Houston	Texas
United States	Mayo Clinic	Jacksonville	Florida
United States	University of California Los Angeles	Los Angeles	California
United States	Mt. Sinai Medical Center	New York	New York
United States	Stanford University	Palo Alto	California
United States	Temple University	Philadelphia	Pennsylvania
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	Barrow Neurosurgical Associates	Phoenix	Arizona
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Virginia Commonwealth University	Richmond	Virginia
United States	University of Texas HSC, San Antonio	San Antonio	Texas
United States	University of California, San Diego	San Diego	California
United States	Georgetown University	Washington	District of Columbia

Sponsors (4)

Lead Sponsor	Collaborator
Daniel Hanley	Emissary International LLC, Genentech, Inc., National Institute of Neurological Disorders and Stroke (NINDS)

Countries where clinical trial is conducted

United States,  Canada,  Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Outcome Number 1: Rate of Mortality	Percentage of participants who died during the first 30 days after randomization.	30 days from randomization	Yes
Primary	Safety Outcome Number 2: Rate of Procedure-related Mortality	Percentage of participants who died during the first 7 days after randomization.	7 days from randomization	Yes
Primary	Safety Outcome Number 3: Rate of Cerebritis, Meningitis, Bacterial Ventriculitis	Percentage of participants who had a bacterial brain infection (cerebritis, meningitis, ventriculitis) within 30 days of randomization.	30 days from randomization	Yes
Primary	Safety Outcome Number 4: Rate of Symptomatic Rebleeding	The difference in the rate of symptomatic rebleeding 72 hours post last dose.	72 hours post last dose	Yes
Primary	Efficacy Outcome Number 1: Dichotomized Modified Rankin Scale (mRS) at Day 180	Percentage of participants with dichotomized mRS score in 0-3 range. The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale ranges from 0-6: (0) no symptoms at all, (1) no significant disability despite symptoms; able to carry out all usual duties and activities, (2) slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance, (3) moderate disability; requiring some help, but able to walk without assistance, (4) moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance, (5) severe disability; bedridden, incontinent and requiring constant nursing care and attention, (6) dead	180 days from randomization	No
Secondary	Ordinal Modified Rankin Scale (mRS) at Day 180	Ordinal distribution of the Modified Rankin Scale score at 180 days. The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale ranges from 0-6: (0) no symptoms at all, (1) no significant disability despite symptoms; able to carry out all usual duties and activities, (2) slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance, (3) moderate disability; requiring some help, but able to walk without assistance, (4) moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance, (5) severe disability; bedridden, incontinent and requiring constant nursing care and attention, (6) dead.	180 days from randomization	No
Secondary	Ordinal Modified Rankin Scale (mRS) at Day 365	Ordinal distribution of the Modified Rankin Scale score at 365 days. The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale ranges from 0-6: (0) no symptoms at all, (1) no significant disability despite symptoms; able to carry out all usual duties and activities, (2) slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance, (3) moderate disability; requiring some help, but able to walk without assistance, (4) moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance, (5) severe disability; bedridden, incontinent and requiring constant nursing care and attention, (6) dead.	365 days from randomization	No
Secondary	Clot Size Reduction by End of Treatment	The percentage of blood clot resolved by the end of treatment CT scan compared to the stability CT scan.	Time from randomization until end of treatment, up to 10 days	No
Secondary	Post-operative Clot Size Reduction	The percentage of blood clot resolved by the end of treatment CT scan compared to the post-operative CT scan for surgical patients.	Time from post-operation until end of treatment, up to 10 days	No

External Links

•   Trial website